Seeking Alpha

Seeking Alpha Portfolio App for iPad

4,042 people get KERX articles and Market Currents by email alert.

Get email alerts on KERX »

KERX

Keryx Biopharmaceuticals, Inc.

5/24/2013, 8:21 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 7, 7:18 PM Keryx (KERX): Q1 EPS of -$0.03 misses by $0.02. Revenue of $7M beats by $1.17M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 9, 1:33 PM Keryx Biopharmaceuticals (KERX +10.9%) trades up on news that a leading patent lawyer will give an opinion on the patent position of it's Zerenex. Concern is that KERX won't be able to protect the phosphate binder from generic challengers. Comment! [Healthcare, On the Move]
Wednesday, March 13, 9:45 AM Keryx Biopharmaceuticals (KERX -0.6%) hires hypertension specialist Amit Sharma to the newly created position of VP of Medical Affairs. The appointment of Sharma, who has a broad-based background in chronic kidney disease and dialysis, comes as Keryx prepares to seek FDA approval for its Zerenex treatment for patients undergoing dialysis. (PR) Comment! [Healthcare]
Friday, March 1, 1:01 PM Midday top 10 gainers: GMXR +56%. RVLT +37%. MTG +24%. ANAC +15%. DECK +14%. NSPH +13%. KERX +13%. ATEC +13%. CRIS +12%. CIDM +12%.
Midday top 10 losers: SCMR -73%. AT -29%. RNIN -23%. LTBR -23%. FWLT -17%. MDR -14%. SUP -13%. SHIP -13%. MNOV -12%. CBMX -12%. Comment! [On the Move]
Monday, February 4, 8:44 AM JMP Securities' Jason Butler jumps to Keryx's (KERX -0.7%) defense today after the stock plummeted 22% on Friday following a report from research firm IPD Analytics that questioned whether the FDA will grant the company New Chemical Entity status for its Zerenex treatment for patients undergoing dialysis. IDP reckons that the active ingredient in Zerenex may be too similar to an existing chemical called Ferriseltz, although Butler begs to differ. 2 Comments [Healthcare, On the Move]
Friday, February 1, 12:45 PM Midday top 10 gainers: OTT +31%. ALIM +25%. BBW +22%. ADNC +21%. PSDV +16%. EDAP +16%. ABAX +15%. CRR +14%. CIS +11%. PMCS +12%.
Midday top 10 Losers: ECTE -31%. EBOD -28%. BCOV -23%. CKH -22%. LTM -20%. KERX -17%. CLSN -14%. SDR -14%. CBMX -11%. PXLW -11%. Comment! [On the Move]
Thursday, January 31, 10:07 AM Keryx Biopharmaceuticals (KERX) prices an offering of 8.2M shares at $8.49 each, which is where the stock closed yesterday. Including a greenshoe option of 1.2M shares, Keryx could raise up to $80.4M; the biotech plans to use the net proceeds to fund the launch of its kidney disease drug Zerenex. Shares +9.3% to $9.28. (PR) Comment! [Healthcare, On the Move]
Thursday, January 31, 9:13 AM Premarket gainers: ORCC +82%. WMS +55%. FTNT +20%. SGMS +15%. JDSU +14%. KERX +14%. ALGN +13%. SWKS +13%. CTXS +12%. ERIC +11%. DCTH +7%. PBI +8%. QCOM +6%. ALU +6%. CXS +6%. FNSR +6%. LVS +6%. UA +5%. IGT +5%.
Losers: CLSN -79%. LQDT -15%. FIO -14%. RIMM -7%. AFFY -7%. RMD -6%. FB -6%. VNR -5%. 1 Comment [On the Move]
Tuesday, January 29, 6:10 PM Keryx Biopharmaceuticals (KERX) announces a $55M secondary offering, with a 30-day option to the book-runner on another 15% of the number of shares sold. The company plans to use the net proceeds to fund its upcoming launch of Zerenex in Q2. J.P. Morgan is acting as the sole book-runner. Shares -7% AH. Comment! [Healthcare, On the Move]
Tuesday, January 29, 3:23 PM Shares of AEterna Zentaris (AEZS +18.5%) shares rocket higher in afternoon trading on the back of cancer drug peer Keryx Pharmaceuticals (KERX +40%) big gains. Volumes are extremely high in AEZS today, with over 4M shares changing hands, compared to the daily average of around 850K. 3 Comments [Healthcare, On the Move]
Tuesday, January 29, 12:45 PM Midday top 10 gainers: MLNK +32%. KERX +30%. SOMH +25%. VTUS +24%. MHH +14%. SWIR +14%. AEZS +11%. CNIT +11%. IBCP +10%. SSBI +10%.
Midday top 10 Losers: OXF -31%. ANAC -21%. VMW -20%. SANM -18%. OCZ -18%. LXK -15%. CTC -13%. GIG -12%. NTGR -11%. SHIP -11%. Comment! [On the Move]
Tuesday, January 29, 9:10 AM Premarket gainers: KERX +18%. PLXT +10%. VLO +8%. OPK +7%. HES +7%. RPRX +6%. AKS +6%.
Losers: OXF -24%. ANAC -23%. VMW -19%. LXK -6%. RBS -6%. STX -6%. EDU -5%. Comment! [On the Move]
Tuesday, January 29, 8:16 AM Keryx Biopharmaceuticals (KERX) up 10.6% premarket after yesterday's 77% rise, with Burrill almost doubling its price target to $11 following positive Phase 3 results for Zerenex. Stifel goes further, saying the drug's patent shelf life could translate into another $6-$14 of "tail" asset value. 1 Comment [Healthcare, On the Move]
Monday, January 28, 12:45 PM Midday top 10 gainers: KERX +79%. FURX +51%. SHIP +39%. CTC +18%. HGSH +17%. SINO +14%. RSH +12%. CPBC +11%. OCZ +11%. ACAD +10%.
Midday top 10 Losers: NVGN -61%. RPRX -27%. JOSB -18%. TRMD -16%. BYFC -15%. JVA -12%. DDD -11%. PRCP -10%. SSYS -9%. AKS -8%. Comment! [On the Move]
Monday, January 28, 9:11 AM Keryx Biopharmaceuticals (KERX) +45.4% premarket on news its Zerenex experimental kidney disease drug had met its late-stage trial goal of reducing phosphate levels in blood. KERX expects to submit a new drug application with the FDA and a marketing authorization application with the EMA for Zerenex in Q2. Comment! [Healthcare, On the Move]
Monday, January 28, 9:10 AM Premarket gainers: FURX +49%. KERX +46%. NTE +14%. SNE +7%. DOLE +7%. HES +6%. GGC +6%. ACAD +5%.
Losers: JOSB -17%. MTG -5%.
Comment! [On the Move]